Sofosbuvir/velpatasvir/voxilaprevir

From WikiProjectMed
Jump to navigation Jump to search

Sofosbuvir/velpatasvir/voxilaprevir
Combination of
SofosbuvirNS5B RNA polymerase inhibitor
VelpatasvirNS5A inhibitor
VoxilaprevirNS3/4A protease inhibitor
Names
Trade namesVosevi
Clinical data
Main usesHepatitis C[1]
Side effectsHeadache, tiredness, diarrhea, trouble sleeping, nausea[2]
Pregnancy
category
  • AU: B1
  • US: N (Not classified yet)
Routes of
use
By mouth (tablets)
External links
AHFS/Drugs.comMonograph
US NLMSofosbuvir/velpatasvir/voxilaprevir
MedlinePlusa617037
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Chemical and physical data
FormulaC111H135F5N17O26PS
Molar mass2281.42 g·mol−1
3D model (JSmol)
  • CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC.CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
  • InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1
  • Key:FMWRYUBVSONSCK-ZYTFCPLVSA-N

Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a combination medication used to treat hepatitis C.[1] It is taken by mouth with food.[1] Effectiveness is greater than 95%.[1]

Common side effects include headache, tiredness, diarrhea, trouble sleeping, and nausea.[2] Other side effects may include hepatitis B reactivation and liver problems.[2] While there is no clear evidence of harm during pregnancy, it has not been well studied in this group.[3] It contains sofosbuvir, velpatasvir, and voxilaprevir, each of which blocks an enzyme required by the virus.[1]

The combination was approved for medical use in the United States and Europe in 2017.[1][2] In the United States 8 weeks of treatment costs about 48,500 USD as of 2021.[4] This amount in the United Kingdom costs the NHS about £30,000.[5]

Medical uses

It is used to treat hepatitis C.[1] It can be used for genotype 1 to 6.[5]

Dosage

It is typically take at a dose of one tablet a day for 8 to 12 weeks.[1]

Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.[1]

Interactions

It should not be used together with certain medicines including:[1]

Society and culture

Vosevi is sold by Gilead Sciences.[6]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.
  2. 2.0 2.1 2.2 2.3 "Sofosbuvir, Velpatasvir, And Voxilaprevir Monograph for Professionals". Drugs.com. Retrieved 14 October 2021.
  3. "Sofosbuvir / velpatasvir / voxilaprevir (Vosevi) Use During Pregnancy". Drugs.com. Retrieved 14 October 2021.
  4. "Vosevi Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 October 2021.
  5. 5.0 5.1 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2021. p. 667. ISBN 978-0-85711-369-6.
  6. "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.

External links

Identifiers: